Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management
{{output}}
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults, with about 30% of cases progressing to metabolic dysfunction-associated steatohepatitis (MASH), which can lead to cirrhosis and hepatocellular carcinoma. Card... ...
